Now showing items 11-20 of 33
Patents and New Product Development in the Pharmaceutical and Biotechnology Industry
(The Georgetown Public Policy Review, 2003-03)
The price of innovation: new estimates of drug development costs.
(J Health Econ, 2003-03)
The research and development costs of 68 randomly selected new drugs were obtained from a survey of 10 pharmaceutical firms. These data were used to estimate the average pre-tax cost of new drug development. The costs of ...
The Ripple Effects of a Restrictive Medicaid Formulary (editorial)
(American Journal of Managed Care, 2003-10)
Returns on R&D for 1990s New Drug Introductions
The Determinants of Pharmaceutical Research and Development Expenditures
(Journal of Evolutionary Economics, 2000)
Spending on postapproval drug safety.
(Health Aff (Millwood), 2006-03)
Withdrawals of high-profile pharmaceuticals have focused attention on post-approval safety surveillance. There have been no systematic assessments of spending on postapproval safety. We surveyed drug manufacturers regarding ...
Encouraging innovative treatment of neglected diseases through priority review vouchers
(Prescribing Cultures and Pharmaceutical Policy in the Asia-Pacific, 2009-09-01)
The distribution of sales revenues from pharmaceutical innovation.
OBJECTIVE: This report updates our earlier work on the returns to pharmaceutical research and development (R&D) in the US (1980 to 1984), which showed that the returns distributions are highly skewed. It evaluates a more ...
Increasing R&D incentives for neglected diseases: Lessons from the Orphan Drug Act
(International Public Goods And Transfer Of Technology Under A Globalized Intellectual Property Regime, 2005)
Distinguished economists, political scientists, and legal experts discuss the implications of the increasingly globalized protection of intellectual property rights for the ability of countries to provide their citizens ...
Patents, Innovation and Access to New Pharmaceuticals
(Journal of International Economic Law, 2002-02)